[
  {
    "ts": null,
    "headline": "These Are The Best Robinhood Stocks To Buy Or Watch Now",
    "summary": "These Are The Best Robinhood Stocks To Buy Or Watch Now",
    "url": "https://finnhub.io/api/news?id=0d6328f6d2b87b97c46cbaab6c6771996c40b484c4d9bb7e7f73995a07f2b250",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1730265194,
      "headline": "These Are The Best Robinhood Stocks To Buy Or Watch Now",
      "id": 131044702,
      "image": "",
      "related": "LLY",
      "source": "DowJones",
      "summary": "These Are The Best Robinhood Stocks To Buy Or Watch Now",
      "url": "https://finnhub.io/api/news?id=0d6328f6d2b87b97c46cbaab6c6771996c40b484c4d9bb7e7f73995a07f2b250"
    }
  },
  {
    "ts": null,
    "headline": "Correction to Eli Lilly to Offer Higher Doses of Obesity Drug Zepbound Article",
    "summary": "Patrik Jonsson is the president of Eli Lilly & Co.'s cardiometabolic health unit. Eli Lilly to Offer Higher Doses of Obesity Drug Zepbound at Discounted Prices, at 9:33 a.m. ET, incorrectly said his...",
    "url": "https://finnhub.io/api/news?id=7d7cbc2821e952457afe7dabf95a688399be04a3c8f15dd73bf39bb12703407d",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740505447,
      "headline": "Correction to Eli Lilly to Offer Higher Doses of Obesity Drug Zepbound Article",
      "id": 132873640,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Patrik Jonsson is the president of Eli Lilly & Co.'s cardiometabolic health unit. Eli Lilly to Offer Higher Doses of Obesity Drug Zepbound at Discounted Prices, at 9:33 a.m. ET, incorrectly said his...",
      "url": "https://finnhub.io/api/news?id=7d7cbc2821e952457afe7dabf95a688399be04a3c8f15dd73bf39bb12703407d"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly to Offer Higher Doses of Obesity Drug Zepbound at Discounted Prices",
    "summary": "Eli Lilly to Offer Higher Doses of Obesity Drug Zepbound at Discounted Prices",
    "url": "https://finnhub.io/api/news?id=24f6dabd6ba649544b1aaa7669f4ba7180fafa823caf48a8e221004e71abf778",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740504480,
      "headline": "Eli Lilly to Offer Higher Doses of Obesity Drug Zepbound at Discounted Prices",
      "id": 132881608,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly to Offer Higher Doses of Obesity Drug Zepbound at Discounted Prices",
      "url": "https://finnhub.io/api/news?id=24f6dabd6ba649544b1aaa7669f4ba7180fafa823caf48a8e221004e71abf778"
    }
  },
  {
    "ts": null,
    "headline": "Columbia Select Large Cap Equity Fund Q4 2024 Commentary",
    "summary": "Columbia Select Large Cap Equity Fund Institutional Class shares returned 3.31% for\nthe three months ending 12/31/2024. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=369b0d4f7df570e328865349cf6db51f8334ceaaecb1211fafe021f4b172669c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740478800,
      "headline": "Columbia Select Large Cap Equity Fund Q4 2024 Commentary",
      "id": 132871223,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1707046352/image_1707046352.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Columbia Select Large Cap Equity Fund Institutional Class shares returned 3.31% for\nthe three months ending 12/31/2024. Click here to read the full commentary.",
      "url": "https://finnhub.io/api/news?id=369b0d4f7df570e328865349cf6db51f8334ceaaecb1211fafe021f4b172669c"
    }
  },
  {
    "ts": null,
    "headline": "Hims & Hers Stumbles as GLP-1 Compounding Ends. Lilly Presses the Advantage.",
    "summary": "Hims & Hers Stumbles as GLP-1 Compounding Ends. Lilly Presses the Advantage.",
    "url": "https://finnhub.io/api/news?id=8d842d83f6441922524668fd84310b88e154005d92e6ffaab42931a7a420916f",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740477240,
      "headline": "Hims & Hers Stumbles as GLP-1 Compounding Ends. Lilly Presses the Advantage.",
      "id": 132881609,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Hims & Hers Stumbles as GLP-1 Compounding Ends. Lilly Presses the Advantage.",
      "url": "https://finnhub.io/api/news?id=8d842d83f6441922524668fd84310b88e154005d92e6ffaab42931a7a420916f"
    }
  },
  {
    "ts": null,
    "headline": "Correction to Eli Lilly Article",
    "summary": "The pharmaceutical company said it has launched 7.5 and 10 milligram single-dose vials of its Zepbound drug, also known as tirzepatide, which join the existing lineup of 2.5 and 5 milligram vials. ...",
    "url": "https://finnhub.io/api/news?id=a465e61f245ff6b4423c2b9dd2a5ae129af27069b25f3dfe39c9b22e20e87681",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740475088,
      "headline": "Correction to Eli Lilly Article",
      "id": 132870856,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "The pharmaceutical company said it has launched 7.5 and 10 milligram single-dose vials of its Zepbound drug, also known as tirzepatide, which join the existing lineup of 2.5 and 5 milligram vials. ...",
      "url": "https://finnhub.io/api/news?id=a465e61f245ff6b4423c2b9dd2a5ae129af27069b25f3dfe39c9b22e20e87681"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Introduces New Weight Loss Drug Doses, Lowers Price Points",
    "summary": "Eli Lilly Introduces New Weight Loss Drug Doses, Lowers Price Points",
    "url": "https://finnhub.io/api/news?id=8f1ac503c7b91424a8cb958a86f247b1cce3c1d18ce4d8e244b76d5c4046e48d",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740474120,
      "headline": "Eli Lilly Introduces New Weight Loss Drug Doses, Lowers Price Points",
      "id": 132881610,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly Introduces New Weight Loss Drug Doses, Lowers Price Points",
      "url": "https://finnhub.io/api/news?id=8f1ac503c7b91424a8cb958a86f247b1cce3c1d18ce4d8e244b76d5c4046e48d"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: Load Up Before It Leaves You Behind",
    "summary": "Eli Lilly stock surges past $840, outperforming the S&P 500. Click here to learn why LLY stock is still undervalued and why now might be the time to invest.",
    "url": "https://finnhub.io/api/news?id=6183741b398eb654368e28be509afd52dc5cbc828a05b05d048a05e3f41802d0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740474000,
      "headline": "Eli Lilly: Load Up Before It Leaves You Behind",
      "id": 132870864,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/521503314/image_521503314.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly stock surges past $840, outperforming the S&P 500. Click here to learn why LLY stock is still undervalued and why now might be the time to invest.",
      "url": "https://finnhub.io/api/news?id=6183741b398eb654368e28be509afd52dc5cbc828a05b05d048a05e3f41802d0"
    }
  },
  {
    "ts": null,
    "headline": "Organovo’s FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company",
    "summary": "SAN DIEGO, Feb. 25, 2025 -- Organovo Holdings, Inc. , a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease today announced that...",
    "url": "https://finnhub.io/api/news?id=a69a67c02941c35a10ad466204dce6976fd976a2186456878734a049ba512d96",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740470767,
      "headline": "Organovo’s FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company",
      "id": 132870327,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "SAN DIEGO, Feb. 25, 2025 -- Organovo Holdings, Inc. , a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease today announced that...",
      "url": "https://finnhub.io/api/news?id=a69a67c02941c35a10ad466204dce6976fd976a2186456878734a049ba512d96"
    }
  },
  {
    "ts": null,
    "headline": "Lilly launches additional Zepbound vial doses and offers new savings for self-pay patients",
    "summary": "New 7.5 mg and 10 mg Zepbound single-dose vials now available for $499 per month via Zepbound Self Pay Journey Program2.5 mg and 5 mg vial prices reducedINDIANAPOLIS, Feb. 25, 2025 /PRNewswire/ --...",
    "url": "https://finnhub.io/api/news?id=9f39e54ccbe84262d0a46965551e1b9ee6abf8f18727f762ff26bf9e37a2bc29",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740465967,
      "headline": "Lilly launches additional Zepbound vial doses and offers new savings for self-pay patients",
      "id": 132869654,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "New 7.5 mg and 10 mg Zepbound single-dose vials now available for $499 per month via Zepbound Self Pay Journey Program2.5 mg and 5 mg vial prices reducedINDIANAPOLIS, Feb. 25, 2025 /PRNewswire/ --...",
      "url": "https://finnhub.io/api/news?id=9f39e54ccbe84262d0a46965551e1b9ee6abf8f18727f762ff26bf9e37a2bc29"
    }
  },
  {
    "ts": null,
    "headline": "Hims & Hers: Why This Q4 Earnings Dip Is A Buying Opportunity",
    "summary": "Hims & Hers dipped 19% post-Q4 earnings. Read here for HIMS stock's growth trends, margin concerns, and why this could be a strong long-term buying opportunity.",
    "url": "https://finnhub.io/api/news?id=dec62c92aca0eba2c7004fa0538e6905cacb7b30b3a3107102e51512220adaf8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740456111,
      "headline": "Hims & Hers: Why This Q4 Earnings Dip Is A Buying Opportunity",
      "id": 132868872,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1428189711/image_1428189711.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Hims & Hers dipped 19% post-Q4 earnings. Read here for HIMS stock's growth trends, margin concerns, and why this could be a strong long-term buying opportunity.",
      "url": "https://finnhub.io/api/news?id=dec62c92aca0eba2c7004fa0538e6905cacb7b30b3a3107102e51512220adaf8"
    }
  },
  {
    "ts": null,
    "headline": "RiverPark Long/Short Opportunity Fund Q4 2024 Investor Letter",
    "summary": "RiverPark Long/Short Opportunity Fund Q4 2024 Investor Letter",
    "url": "https://finnhub.io/api/news?id=12f99051ab75176698da48399b15c88c298d14556e1797372b9cd142190233dc",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740450300,
      "headline": "RiverPark Long/Short Opportunity Fund Q4 2024 Investor Letter",
      "id": 132868374,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=12f99051ab75176698da48399b15c88c298d14556e1797372b9cd142190233dc"
    }
  }
]